facebook
twitter
rss
account
search
search

FDA committee advises approval of Breo, a COPD drug

April 18, 2013 at 12:25 AM   |   Comments

WASHINGTON, April 18 (UPI) -- The U.S. Food and Drug Advisory Committee recommended approval of Breo Ellipta for the treatment of chronic obstructive pulmonary disease, officials say.

GlaxoSmithKline and Theravance Inc. said the Pulmonary-Allergy Drugs Advisory Committee to the FDA voted the efficacy and safety data providedobstruction in patients with COPD -- 9 for, 4 against.

"We are pleased with the outcome of today's meeting. COPD is a substantial evidence to support approval of Breo Ellipta as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives," Patrick Vallance, GSK's president of pharmaceuticals, research and development, said in a statement.

"This positive recommendation is a crucial first step towards making Breo Ellipta available for appropriate COPD patients across the United States. We look forward to a final decision from the FDA later this year."

© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Florida health official says Vibrio not 'flesh-eating'
2
Cheesecake Factory is America's most unhealthy food franchise
3
Florida health officials warn of flesh-eating bacteria
4
CDC: Ebola not a significant threat to United States
5
Skin cancer is 'major public health problem,' surgeon general says
Trending News
Video
x
Feedback